Bristol-Myers Taps Academia To Help Research Immuno-Oncology Pipeline
This article was originally published in The Pink Sheet Daily
Inspired by the correlative research during the clinical trials for Yervoy, BMS teams up with ten institutions from across the globe to find biomarkers in post-response data.
You may also be interested in...
Deals with a wide range of companies and academic institutions are exploring nivolumab’s horizons in many solid and hematological malignancies.
The potential for cancer immunotherapy was the clear takeaway from ASCO 2013. With a lead on the competition, a portfolio with a variety of intriguing mechanisms and many combination trials ongoing, Bristol looks to take immuno-oncology development to the next level.
Bristol-Myers Squibb forms an alliance with Emory University to conduct mid- and late-stage trials in oncology, metabolics, hepatitis C, and immunoscience using BMS compounds.